Potential use of neuroprotective and L-DOPA-rich plants in parkinsonian therapy-Reference-Cited by-同舟云学术

Potential use of neuroprotective and L-DOPA-rich plants in parkinsonian therapy

Published:2023-12-30 Issue: Volume: Page:1-10
ISSN:2456-3927
Container-title:NeuroPharmac Journal
language:en
Short-container-title:NeuroPharmac J

Author:

Arif Jamal¹^ORCID,Jamal Yusuf²^ORCID,Almarshad Feras³^ORCID,Alshahrani Abdulrahman⁴^ORCID,Atef Mohammed⁵

Affiliation:

1. Department of Basic Medical Sciences, College of Medicine, Shaqra University, Shaqra, Saudi Arabia.

2. Ternopil National Medical University, Ternopil, Ukraine

3. Department of Internal Medicine, College of Medicine, Shaqra University, Shaqra, Saudi Arabia

4. Department of Internal Medicine (Neurology), College of Medicine, Shaqra University, Shaqra, Saudi Arabia

5. Department of Basic Medical Sciences, College of Medicine, Shaqra University, Shaqra, Saudi Arabia

Abstract

Parkinson’s Disease (PD) is a prevalent movement disorder among the population with more than 10 million living with PD worldwide. L-DOPA has been a drug of choice in the treatment of PD for a long time due to its potential to cross the blood-brain barrier. However, prolonged use of synthetic L-DOPA also exerted toxicities in the patients. A significant number of research studies have been documented for a promising future of using natural L-DOPA resources for the management of PD or perhaps delaying the onset of PD. This review will highlight the potential of some of the natural L-DOPA sources and neuroprotective agents used in PD management.

Publisher

Author Gate Publications

Subject

General Medicine

Reference57 articles.

1. Qamar MA, Rota S, Batzu L, et al. Chaudhuri's Dashboard of Vitals in Parkinson's syndrome: an unmet need underpinned by real life clinical tests. Front Neurol. 2023;14:1174698.

2. N. Maserejian, L. Vinikoor-Imler, A. Dilley. Estimation of the 2020 Global Population of Parkinson’s Disease (PD) [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/estimation-of-the-2020-global-population-of-parkinsons-disease-pd/. Accessed December 28, 2023.

3. Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis. 2018;4:21.

4. Lee ES, Chen H, King J, Charlton C. The role of 3-O-methyldopa in the side effects of L-dopa. Neurochem Res. 2008;33(3):401-411.

5. Zaman V, Shields DC, Shams R, et al. Cellular and molecular pathophysiology in the progression of Parkinson's disease. Metab Brain Dis. 2021;36(5):815-827.